Samsung Biologics' third CDMO production facility in Songdo, Incheon / Courtesy of Samsung Biologics

Samsung Biologics, the biotech arm of Korea's Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding an mRNA vaccine ingredient production facility at the plant, a company official said Thursday.

According to the official, Samsung has completed the addition of the new mRNA vaccine ingredient production capability at its plant in Songdo, Incheon, 40 kilometers west of Seoul, and began producing it for COVID-19 vaccines made by GreenLight Biosciences of the United States late last month.

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), signed a drug ingredient supply agreement with the American biotech company last year.

The Korean biotech company now has the full range of capacity to produce mRNA vaccines from ingredients production to final packaging.

Last year, Samsung Biologics also won a contract from Moderna to provide CDMO services for the U.S. biotech company's mRNA COVID-19 vaccines. (Yonhap)